NVE Corporation 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for NVE Corporation for the period ended September 30, 2010. NVE develops and sells devices utilizing spintronics, a nanotechnology relying on electron spin to acquire, store, and transmit information. The company manufactures high-performance sensors and couplers and licenses MRAM technology. As of October 15, 2010, there were 4,700,583 shares of common stock outstanding.
Key Financial Metrics
| Metric | Quarter Ended Sept 30, 2010 | Six Months Ended Sept 30, 2010 |
|---|---|---|
| Total Revenue | $7,809,160 | $15,050,454 |
| Net Income | $3,206,010 | $6,307,107 |
| Diluted EPS | $0.66 | $1.30 |
| Gross Margin | 66.6% | 68.9% |
| Operating Cash Flow (6mo) | $5,710,011 | |
| Cash & Equivalents | $690,841 (as of Sept 30, 2010) | |
| Marketable Securities | $55,209,828 (Total Fair Value) | |
| Total Assets | $64,717,434 | |
| Debt | None reported |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 20% for the quarter and 13% for the six-month period compared to the prior year. This was driven primarily by a 24% increase in product sales due to new customers and increased volume from existing customers.
- Profitability: Net income rose 19% for the quarter and 12% for the six-month period. Gross profit margins decreased slightly (from 69.5% to 66.6% for the quarter) due to a less favorable product sales mix.
- Expenses: Total expenses increased 3% for the quarter, driven by a 6% rise in R&D expenses due to increased product development activities.
- Interest Income: Interest income increased 27% for the quarter and 28% for the six-month period, attributed to a larger portfolio of interest-bearing marketable securities.
- Inventory: Inventories increased by $665,300 over the six-month period to support higher sales rates and due to raw material purchase timing.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes working capital is adequate for the next 12 months. The company holds approximately 85% of its total assets in marketable securities ($55.2 million).
- Capital Expenditures: Purchases of fixed assets were $204,419 for the six months ended September 30, 2010. Management expects a higher quarterly rate of purchases for the remainder of the fiscal year to expand production capacity.
- Key Risks:
- Customer Concentration: Significant revenue depends on agreements with large customers (St. Jude Medical, Phonak AG, Avago Technologies). Failure to renew these agreements could materially impact revenue.
- Investment Risk: The company holds a significant portfolio of marketable securities. Downgrades or defaults (citing the BP Capital Markets plc example) could result in material losses.
- Contract Fluctuation: Contract research and development revenue is volatile and not necessarily indicative of future quarters.
- Unusual Items: No unusual items were reported. Stock-based compensation decreased compared to the prior year due to lower stock prices at the date of grant.
Investor Verification Checklist
- Verify the renewal status and terms of supply agreements with major customers: St. Jude Medical (expires Dec 2011), Phonak AG (expires May 2012), and Avago Technologies (expires June 2013).
- Monitor the credit quality and unrealized gains/losses of the $55.2 million marketable securities portfolio, which represents 85% of total assets.
- Assess the sustainability of the 24% increase in product sales and whether it is driven by one-time volume or recurring demand.
- Review the impact of the "less favorable product sales mix" on future gross margin trends.
- Confirm the timeline and capital requirements for the planned expansion of production capacity.